One Healthcare stock on the watchlist – Nanosonic Limited

nanosonic healthcare stocks

Nanosonics’ stock continues to slide lower as the company’s revenue has squeezed in the financial year ended 30 June 2018. However, the FY18 results were in line with investor’s expectation as the company has heavily invested in its next generation Trophon2 which is anticipated to boost the company’s future revenue.

Last month, infection control specialist Nanosonics Limited reported decline of 10% in the company’ total sales to $60.7 million in FY18, delivering lower operating profit before tax of $5.6 million, compared with $13.9 million in the prior year.

The company indicated that this downturn in revenue is directly attributable to reduction in capital revenue and customer deferring purchases associated with advanced disinfection device, trophon2.                                                                                                  [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

In the previous year, NAN has received approval for trophon2 from USA in April 2018 and from Europe in June 2018, following which the company has launched next generation device Trophon2 in first quarter of FY19. It is a next generation disinfection device which promises to provide the most advanced ultrasound high level disinfection solution in the world.

With the profound launch of the second generation trophon2 device, the company is expected to deliver promising results in the future. Further, the company visions to establish their Trophon technology as a standard of care with an expected launch of one or more new products by the end of FY20.

NAN share price has fallen by 1.54% to $3.2 on 13 September 2018 (4:40 PM AEST). There has been a performance change of 19.49% over the past one year. As of now, the stock traded at PE of 169.270 x with market capitalization of circa $972.87 million.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report